# A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))

> **NCT07034209** · PHASE2 · COMPLETED · sponsor: **TJ Biopharma Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Hemophagocytic Lymphohistiocytoses

## Interventions

- **DRUG:** Plonmarlimab

## Key facts

- **NCT ID:** NCT07034209
- **Lead sponsor:** TJ Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-07
- **Primary completion:** 2025-04-18
- **Final completion:** 2025-04-18
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07034209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07034209, "A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07034209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*